المؤلفون: Liu W; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, PR China. Electronic address: liuweilulucky@163.com., Li Q; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, PR China., Han Q; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.

المصدر: Biosensors & bioelectronics [Biosens Bioelectron] 2024 Aug 15; Vol. 258, pp. 116348. Date of Electronic Publication: 2024 May 03.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Advanced Technology Country of Publication: England NLM ID: 9001289 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4235 (Electronic) Linking ISSN: 09565663 NLM ISO Abbreviation: Biosens Bioelectron Subsets: MEDLINE

مواضيع طبية MeSH: Etoposide*/analysis , Etoposide*/administration & dosage , Needles* , Biosensing Techniques*/instrumentation , Gold*/chemistry , Drug Monitoring*/instrumentation, Animals ; Rats ; Electrochemical Techniques/methods ; Antineoplastic Agents/analysis ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/blood ; Metal Nanoparticles/chemistry ; Molecularly Imprinted Polymers/chemistry ; Limit of Detection ; Electrodes ; Rats, Sprague-Dawley ; Equipment Design

المؤلفون: Moukhtari SHE; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, Universidad de Navarra, C/Irunlarrea 1, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008, Pamplona, Spain., Muñoz-Juan A; Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193, Bellaterra, Spain., Del Campo-Montoya R; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, Universidad de Navarra, C/Irunlarrea 1, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008, Pamplona, Spain., Laromaine A; Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193, Bellaterra, Spain. alaromaine@icmab.es., Blanco-Prieto MJ; Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, Universidad de Navarra, C/Irunlarrea 1, 31008, Pamplona, Spain. mjblanco@unav.es.; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008, Pamplona, Spain. mjblanco@unav.es.

المصدر: Drug delivery and translational research [Drug Deliv Transl Res] 2024 Aug; Vol. 14 (8), pp. 2158-2169. Date of Electronic Publication: 2024 Feb 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE

مواضيع طبية MeSH: Etoposide*/administration & dosage , Etoposide*/chemistry , Caenorhabditis elegans*/drug effects , Apoptosis*/drug effects, Animals ; Humans ; Cell Line, Tumor ; Nanomedicine ; Lipids/chemistry ; Lipids/administration & dosage ; Nanoparticles/administration & dosage ; Nanoparticles/chemistry ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/chemistry ; Antineoplastic Agents, Phytogenic/pharmacology ; Cell Survival/drug effects ; Cell Proliferation/drug effects ; Particle Size

المؤلفون: Tang FF; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Duan WB; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Liu XH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Lu SY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zhao XS; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Jia JS; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Wang J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Gong LZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Zhao T; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Shi HX; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Chang YJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China., Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China., Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.

المصدر: British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 510-516. Date of Electronic Publication: 2024 Apr 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Etoposide*/administration & dosage , Etoposide*/therapeutic use , Induction Chemotherapy*/methods , Leukemia, Promyelocytic, Acute*/drug therapy , Leukemia, Promyelocytic, Acute*/mortality, Humans ; Male ; Female ; Middle Aged ; Adult ; Administration, Oral ; Retrospective Studies ; Infusions, Intravenous ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; COVID-19 ; Tretinoin/administration & dosage ; Tretinoin/therapeutic use ; SARS-CoV-2 ; Remission Induction ; Arsenic/administration & dosage ; Aged

المؤلفون: Zhu Z; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Li X; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.; Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, China., Yuan X; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Chen X; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Lin T; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Guo X; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Li N; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.; Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, China.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jul 18; Vol. 15, pp. 1439253. Date of Electronic Publication: 2024 Jul 18 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Etoposide*/administration & dosage , Etoposide*/therapeutic use , Hematopoietic Stem Cell Mobilization*/methods , Cytarabine*/administration & dosage , Cytarabine*/therapeutic use , Granulocyte Colony-Stimulating Factor*/administration & dosage , Lymphoma*/therapy , Lymphoma*/mortality , Lymphoma*/drug therapy, Humans ; Male ; Female ; Adult ; Middle Aged ; Retrospective Studies ; Aged ; Young Adult ; Hematopoietic Stem Cell Transplantation/methods ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Recurrence ; Treatment Outcome ; Adolescent

المؤلفون: Hu J; Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Wang J; Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China., Wang Z; Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

المصدر: Frontiers in immunology [Front Immunol] 2024 Jul 08; Vol. 15, pp. 1415597. Date of Electronic Publication: 2024 Jul 08 (Print Publication: 2024).

نوع المنشور: Journal Article; Clinical Trial

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Etoposide*/administration & dosage , Etoposide*/adverse effects , Etoposide*/therapeutic use , Lymphohistiocytosis, Hemophagocytic*/drug therapy , Lymphohistiocytosis, Hemophagocytic*/mortality , Benzamides*/administration & dosage , Benzamides*/adverse effects , Benzamides*/therapeutic use , Glucocorticoids*/administration & dosage , Glucocorticoids*/therapeutic use , Glucocorticoids*/adverse effects , Aminopyridines*/administration & dosage , Aminopyridines*/adverse effects , Aminopyridines*/therapeutic use, Humans ; Male ; Female ; Adult ; Middle Aged ; Treatment Outcome ; Aged ; Drug Therapy, Combination ; Histone Deacetylase Inhibitors/therapeutic use ; Histone Deacetylase Inhibitors/adverse effects ; Histone Deacetylase Inhibitors/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

المؤلفون: Nakao S; Department of Hematology, Toho University Sakura Medical Center, Japan., Tanaka S; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan., Abe K; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan., Komiyama T; Center for Diabetes, Metabolism, and Endocrinology, Toho University Sakura Medical Center, Japan., Sugiura Y; Department of Surgical Pathology, Toho University Sakura Medical Center, Japan., Nakaseko C; Department of Hematology, International University of Health and Welfare School of Medicine, Japan., Shimizu N; Department of Hematology, Toho University Sakura Medical Center, Japan.

المصدر: Internal medicine (Tokyo, Japan) [Intern Med] 2024 Jul 01; Vol. 63 (13), pp. 1923-1927. Date of Electronic Publication: 2023 Nov 20.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Japanese Society of Internal Medicine Country of Publication: Japan NLM ID: 9204241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7235 (Electronic) Linking ISSN: 09182918 NLM ISO Abbreviation: Intern Med Subsets: MEDLINE

مواضيع طبية MeSH: Rituximab*/therapeutic use , Rituximab*/administration & dosage , Cyclophosphamide*/therapeutic use , Cyclophosphamide*/administration & dosage , Mediastinal Neoplasms*/drug therapy , Mediastinal Neoplasms*/diagnostic imaging , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Lymphoma, Large B-Cell, Diffuse*/drug therapy , Vincristine*/therapeutic use , Vincristine*/administration & dosage , Transgender Persons* , Doxorubicin*/therapeutic use , Doxorubicin*/administration & dosage , Prednisone*/therapeutic use , Prednisone*/administration & dosage , Etoposide*/administration & dosage , Etoposide*/therapeutic use, Humans ; Female ; Treatment Outcome ; Adult

SCR Protocol: EPOCH protocol

المؤلفون: Zhang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Yang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou T; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen G; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou H; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Ma Y; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Hong S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao H; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. zhangli@sysucc.org.cn., Fang W; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. fangwf@sysucc.org.cn.

المصدر: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Sep 27; Vol. 9 (1), pp. 255. Date of Electronic Publication: 2024 Sep 27.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Etoposide*/administration & dosage , Etoposide*/adverse effects , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Aged ; Adult

المؤلفون: Zain J; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Tsai NC; Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA., Palmer J; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.; Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA., Simpson J; Clinical Trials Office, City of Hope National Medical Center, Duarte, CA., Adhikarla V; Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA., Bading JR; Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA., Yazaki P; Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA., Smith EP; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Dandapani S; Department of Radiology, City of Hope National Medical Center, Duarte, CA., Song JY; Department of Pathology, City of Hope National Medical Center, Duarte, CA., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Salhotra A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Nademanee AP; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Nakamura R; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Smith DL; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Yamauchi D; Department of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA., Poku EK; Radiopharmacy, City of Hope National Medical Center, Duarte, CA., Biglang-Awa VE; Radiopharmacy, City of Hope National Medical Center, Duarte, CA., Colcher D; Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA., Shively JE; Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA., Wu AM; Department of Immunology and Theranostics, City of Hope National Medical Center, Duarte, CA., Forman SJ; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Wong J; Department of Radiology, City of Hope National Medical Center, Duarte, CA., Thomas S; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

المصدر: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4812-4822.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/methods , Carmustine*/therapeutic use , Carmustine*/administration & dosage , Lymphoma, T-Cell, Peripheral*/therapy , Lymphoma, T-Cell, Peripheral*/mortality , Melphalan*/therapeutic use , Melphalan*/administration & dosage , Transplantation Conditioning*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Cytarabine*/therapeutic use , Cytarabine*/administration & dosage , Transplantation, Autologous* , Etoposide*/therapeutic use , Etoposide*/administration & dosage, Humans ; Middle Aged ; Female ; Male ; Adult ; Aged ; Interleukin-2 Receptor alpha Subunit ; Podophyllotoxin/therapeutic use ; Podophyllotoxin/administration & dosage ; Treatment Outcome

المؤلفون: Zeller B; Department of Pediatric Hematology-Oncology, Oslo University Hospital, Oslo. bzeller@ous-hf.no., Arad-Cohen N; Department of Pediatric Hemato-Oncology, Rambam Health Care Campus, Haifa., Cheuk D; Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital and Hong Kong Pediatric Hematology and Oncology Study Group (HKPHOSG), Hong Kong., De Moerloose B; Department of Pediatric Hematology-Oncology, Ghent University Hospital, Gent., Navarro JMF; Department of Pediatric Hemato-Oncology, Hospital Universitario y Politecnico La Fe, Valencia., Hasle H; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus., Jahnukainen K; New Children's hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Juul-Dam KL; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus., Kaspers G; Princess Maxima Center for Pediatric Oncology, Utrecht, and Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam., Kovalova Z; Department of Pediatric Oncology/Hematology, Children's Clinical University Hospital, Riga, Latvia., Jonsson OG; Department of Pediatrics, Landspitali University Hospital, Reykjavik, Iceland., Lausen B; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen., Munthe-Kaas M; Department of Pediatric Hematology-Oncology, Oslo University Hospital, Oslo., Nystrom UN; Department of Clinical Sciences, Pediatrics, Umea University, Umea., Palle J; Department of Women's and Children's Health, Uppsala University, Uppsala., Pasauliene R; Center of Oncology and Hematology, BMT Unit, Vilnius University Children's Hospital, Vilnius, Lithuania., Pronk CJ; Childhood Cancer Center, Skane University Hospital, Lund., Saks K; Department of Pediatrics, SA Tallinna Lastehaigla, Tallinn, Estonia., Tierens A; Laboratory Medicine Program, Hematopathology, University Health Network, Toronto, ON, Canada., Abrahamsson J; Institution for Clinical Sciences, Department of Pediatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg.

المصدر: Haematologica [Haematologica] 2024 Sep 01; Vol. 109 (9), pp. 2873-2883. Date of Electronic Publication: 2024 Sep 01.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/therapy , Leukemia, Myeloid, Acute*/mortality , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/diagnosis , Leukocytosis*/therapy , Leukapheresis* , Etoposide*/administration & dosage , Etoposide*/therapeutic use, Humans ; Child ; Female ; Male ; Child, Preschool ; Infant ; Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Treatment Outcome ; Disease Management ; Leukocyte Count

المؤلفون: Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. moto19781205@yahoo.co.jp., Iwasawa S; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Sasaki Y; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Tajima K; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Chiba Y; Kinki University Hospital, Osaka, Japan.

المصدر: Advances in therapy [Adv Ther] 2024 Sep; Vol. 41 (9), pp. 3539-3556. Date of Electronic Publication: 2024 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE

مواضيع طبية MeSH: Carboplatin*/therapeutic use , Carboplatin*/adverse effects , Small Cell Lung Carcinoma*/drug therapy , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Lung Neoplasms*/drug therapy , Etoposide*/therapeutic use , Etoposide*/adverse effects , Etoposide*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Databases, Factual*, Humans ; Male ; Female ; Aged ; Japan ; Middle Aged ; Retrospective Studies ; Adult ; Aged, 80 and over ; East Asian People